The leading global hygiene and health company Essity has acquired the distribution rights to the wound care technology Sorbact in Australia and New Zealand from the Australian company Bayport Brands. In 2020, sales of Sorbact in the region amounted to A$1.7 million (Australian dollar). Sorbact is used in wound care products to prevent and treat infections.

 

“This acquisition underlines our ambition to accelerate growth in advanced wound care, where we showed good organic sales growth during the second half of 2020. It is also a good fit for our strategy to establish a stronger presence in Australia and New Zealand, where we – in addition to our successful medical solutions operations – are also in the final phase of the acquisition of Asaleo Care,” Magnus Groth, president and CEO of Essity, said in a press release.

 

Sorbact is a clinically established innovation for advanced wound care, which is manufactured and marketed by Abigo Medical. Essity acquired 75 per cent of Abigo Medical in February 2020.

 

Sorbact treats infections using a natural mode of action that binds bacteria and fungi. Sorbact does not contain antiseptics or other toxic substances, which is positive for both the patient and the environment.